CRVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Corvus Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2025 was $9.28
The historical data trend for Corvus Pharmaceuticals's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Current Liabilities | Get a 7-Day Free Trial |
![]() |
![]() |
12.15 | 9.69 | 10.75 | 6.87 | 35.40 |
Corvus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Total Current Liabilities | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6.72 | 13.34 | 46.41 | 35.40 | 9.28 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Corvus Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 5.198 | + | 0.185 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 30.019 | + | 0 | |
= | 35.40 |
Corvus Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2025 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 4.157 | + | 0.319 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 4.803 | + | 0 | |
= | 9.28 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
William Benton Jones | officer: See Remarks | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Miller Richard A Md | director, officer: President and CEO | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Linda S Grais | director | 86 ALEJANDRA AVE, ATHERTON CA 94027 |
Leiv Lea | officer: Chief Financial Officer | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Edith P. Mitchell | director | 1640 MARENGO ST., LOS ANGELES CA 90033 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Mehrdad Mobasher | officer: Chief Medical Officer | 863 MITTEN ROAD, BURLINGAME CA 94010 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
Terry P Gould | director, 10 percent owner | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Joseph J Buggy | officer: EVP Discovery Research | CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Daniel W. Hunt | officer: SVP, Chief Business Officer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Erik J. Verner | officer: V.P., Chemistry Research | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
From GuruFocus
By Marketwired • 01-13-2025
By Marketwired • 09-10-2024
By Marketwired • 02-04-2025
By Marketwired • 07-31-2024
By Marketwired • 08-01-2024
By Marketwired • 11-14-2024
By Marketwired • 04-09-2025
By Marketwired • 11-09-2024
By Marketwired • 03-19-2025
By GuruFocus News • 02-14-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.